EUVIMEDEUVIMED entdecken
Crossref

Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2

Kathleen A Ross, Sean Kelly, Kruttika S Phadke, Nathan Peroutka-Bigus, Olufemi Fasina, Alaric Siddoway, Surya K Mallapragada, Michael J Wannemuehler, Bryan H Bellaire, Balaji Narasimhan

Acta Biomaterialia · 2024

DOI: 10.1016/j.actbio.2024.05.048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2024. Verfasst von Kathleen A Ross und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nanovaccine Institute, Iowa State University, Ames, IA 50011, USA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Nanovaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While first generation SARS-CoV-2 vaccines were effective in slowing the spread and severity of disease during the COVID-19 pandemic, there is a need for vaccines capable of inducing durable and broad immunity against emerging variants of concern. Nanoparticle-based vaccines (i.e., "nanovaccines") composed of polyanhydride nanoparticles and pentablock copolymer micelles have previously been shown to protect against respiratory pathogens, including influenza A virus, respiratory syncytial virus, and Yersinia pestis. In this work, a nanovaccine containing SARS-CoV-2 spike and nucleocapsid antigens was designed and optimized. The optimized nanovaccine induced long-lived systemic IgG antibody responses against wild-type SARS-CoV-2 virus. In addition, the nanovaccine induced antibody responses capable of neutralization and cross-reactivity to multiple SARS-CoV-2 variants (including B.1.1.529) and antigen-specific CD4+ and CD8+ T cell responses. Finally, the nanovaccine protected mice against a lethal SARS-CoV-2 challenge, setting the stage for advancing particle-based SARS-CoV-2 nanovaccines. STATEMENT OF SIGNIFICANCE: First-generation SARS-CoV-2 vaccines were effective in slowing the spread and limiting the severity of COVID-19. However, current vaccines target only one antigen of the virus (i.e., spike protein) and focus on the generation of neutralizing antibodies, which may be less effective against new, circulating strains. In this work, we demonstrated the ability of a novel nanovaccine platform, based on polyanhydride nanoparticles and pentablock copolymer micelles, to generate durable and broad immunity against SARS-CoV-2. These nanovaccines induced long-lasting (> 62 weeks) serum antibody responses which neutralized binding to ACE2 receptors and were cross-reactive to multiple SARS-CoV-2 variants. Additionally, mice immunized with the SARS-CoV-2 nanovaccine showed a significant increase of antigen-specific T cell responses in the draining lymph nodes and spleens. Together, these nanovaccine-induced immune responses contributed to the protection of mice against a lethal challenge of live SARS-CoV-2 virus, indicating that this nanovaccine platform is a promising next-generation SARS-CoV-2 vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesNanovaccinesAnimalsFemaleHumansMiceAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesMice, Inbred BALB CMicellesPolyanhydridesSARS-CoV-2Spike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

Antigen-specific T cellNanovaccineNeutralizing antibodySARS-CoV-2

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesMicellesNanovaccinesPolyanhydridesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Nanovaccine Institute, Iowa State University, Ames, IA 50011, USA.
  • Nanovaccine Institute, Iowa State University, Ames, IA 50011, USA; Chemical & Biological Engineering, Iowa State University, Ames, IA 50011, USA.
  • Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA 50011, USA.
  • Veterinary Pathology, Iowa State University, Ames, IA 50011, USA.
  • Nanovaccine Institute, Iowa State University, Ames, IA 50011, USA; Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA 50011, USA.
  • Nanovaccine Institute, Iowa State University, Ames, IA 50011, USA; Chemical & Biological Engineering, Iowa State University, Ames, IA 50011, USA. Electronic address: nbalaji@iastate.edu.

Zitieren

APA

Ross, K. A., Kelly, S., Phadke, K. S., Peroutka-Bigus, N., Fasina, O., Siddoway, A., Mallapragada, S. K., Wannemuehler, M. J., Bellaire, B. H., & Narasimhan, B. (2024). Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2024.05.048

Vancouver

Ross KA, Kelly S, Phadke KS, Peroutka-Bigus N, Fasina O, Siddoway A, et al. Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2. Acta Biomaterialia. 2024. doi:10.1016/j.actbio.2024.05.048

BibTeX
@article{Ross2024,
  author = {Ross, Kathleen A and Kelly, Sean and Phadke, Kruttika S and Peroutka-Bigus, Nathan and Fasina, Olufemi and Siddoway, Alaric and Mallapragada, Surya K and Wannemuehler, Michael J and Bellaire, Bryan H and Narasimhan, Balaji},
  title = {Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2},
  journal = {Acta Biomaterialia},
  year = {2024},
  doi = {10.1016/j.actbio.2024.05.048}
}
Kostenlos starten →